Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

The in vivo results of QPI-1007 mark a new era for Quark. We can now rely solely on internally-developed novel compositions and proprietary siRNA structures to develop products that have the potential to provide greater efficacy than current treatments. The breadth of our new structures allows us to selectively pick the most efficacious, stable siRNA structure, which is the most suitable for the specific sequence."

Dr. Logan stated, "QPI-1007 displayed significant neuroprotective activity compared to untreated controls and two different control siRNA molecules in our in vivo model. These results are very exiting. They show that QPI-1007 is a promising drug for ocular neuroprotection."

Dr. Di Polo commented, "The characteristic visual field changes and loss of vision in glaucoma are caused by the selective degeneration of retinal ganglion cells. Our results suggest that QPI-1007 may be an effective neuroprotective therapy for retinal ganglion cells in acute injuries such as non-artheritic ischemic optic neuropathy, and also in slow-progressing chronic optic nerve injuries such as glaucoma. QPI-1007 has the potential to serve an unmet medical need for these indications."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to target tissues including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801, licensed to Pfizer. In
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Decision Resources Group finds that the ... , China , India , ... strong rate through 2023. Dental implant procedure volumes will grow as ... rises. Other key findings from Decision Resources Group,s coverage ... , Dental implant penetration: Penetration of dental implants ...
(Date:9/30/2014)... Sept. 30, 2014 A study using a ... a new look at the composition of carotid artery ... understand and treat the disease, a leading cause of ... Health Lexington between September 2010 and May 2012, was ... Journal of the American College of Cardiology (JACC) Cardiovascular ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2
... 2011 WaferGen Biosystems, Inc. (OTC Bulletin Board: ... analysis systems, today announced that it will present an ... Business Development and Investment Conference for emerging healthcare and ... Healthcare Conference in San Francisco, January 11-13, 2011.   ...
... DUBLIN, Jan. 7, 2011 Amarin Corporation plc (Nasdaq: ... company with a focus on cardiovascular disease, today announced ... offering of American Depositary Shares ("ADSs"), the underwriters of ... purchase up to an aggregate of 1,800,000 additional ADSs ...
Cached Medicine Technology:WaferGen to Present at OneMedForum San Francisco 2011 2Amarin Announces Underwriters' Exercise of Over-Allotment Option 2Amarin Announces Underwriters' Exercise of Over-Allotment Option 3Amarin Announces Underwriters' Exercise of Over-Allotment Option 4
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new patient ... higher rates than other primary care practices (non-FQHCs), ... to results of a new 10-state University of ... Care . , Using data from a previous ... the investigators found that FQHCs community health ...
(Date:9/30/2014)... EverStryke , the permanent match currently offered ... with a free book and class all about survival education ... an investigative review. , “Joe Marshall of SurvivalLife.com is ... preparation niche, and this product is an excellent way to ... products that Joe offers on his website to help people ...
(Date:9/30/2014)... For most families, fall means back-to-school pictures and ... annual festival. For millions of children, fall also means ... infection Enterovirus D68. , While symptoms mimic the ... especially children with weakened immune systems – can develop ... prompting hospitals across the country to enact visitor restrictions. ...
(Date:9/30/2014)... September 30, 2014 Dr. Karl R.O.S. ... pain program of care that is dramatically improving ... His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, multi-dimensional ... It also addresses sources of inflammation, neurology of the ... “neurokinetic chain” from the brain to the spine, to ...
(Date:9/30/2014)... Defense has made progress in reducing the stigma associated ... and post-traumatic stress disorder, but more improvement is still ... Despite efforts of both the Defense Department and the ... service members still do not seek needed care for ... concerted effort to promote treatment as a way to ...
Breaking Medicine News(10 mins):Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3
... Call to Occur on Wednesday, April 30 at 2 ... Vermillion, Inc.,(Nasdaq: VRML ), a molecular diagnostics company, ... improved detection of peripheral,artery disease (PAD) and to provide ... in late-stage development. The,teleconference will take place on Wednesday, ...
... ten years,after its arrival in the United States, ... surgery is coming under fire from some patients ... Last Friday, the FDA heard testimony from patients ... ranged from mild,visual distortion, to pain, to severe ...
... SPRINGFIELD, Ill., April 28 Does your child,suffer ... an opportunity to,attend a summer camp designed specifically for ... and,physicians? The American Lung Association of Illinois is planning ... sites this year.,During the week of July 6-11, our ...
... TORONTO, April 28 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition" ... announced that,Dr. Tony Cruz, Chairman and Chief Executive ... Healthcare Unplugged Conference. Dr. Cruz,s,presentation will take place ... (Eastern,Time) at the Ritz-Carlton in Key Biscayne, Florida., ...
... study finds , , MONDAY, April 28 (HealthDay News) -- ... food they could ingest not only lost weight, they also ... new report. , Thirty-eight morbidly obese patients with low ... pain decreased by an average of about 44 percent six ...
... UPTON, NY - Brain-imaging studies performed in animals at ... provide researchers with clues about why an increasingly popular ... humans is abused. Using trace amounts of Salvia divinorum ... that can be smoked in the form of dried ...
Cached Medicine News:Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 2Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 3Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 4Health News:FDA Examines LASIK Surgery Complications 2Health News:Transition Therapeutics to Present at 2008 Morgan Stanley Global Healthcare Unplugged Conference 2Health News:Gastric Bypass May Also Relieve Low Back Pain 2Health News:Brookhaven scientists explore brain's reaction to potent hallucinogen 2
... laser-cut stent, is the latest in a ... use after coronary arteries have been opened ... as percutaneous transluminal coronary angioplasty (PTCA). The ... features designed to optimize scaffolding, radiopacity and ...
... The balloon catheter ... balloon design and is ... Gas is contained in ... procedural safety. Radiopaque markings ...
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
... Utilizing technology developed over Guidants 20-year ... the new foundation for successful treatment outcomes. ... tip design with a lower profile shaft,more ... Now you can cross tight and tortuous ...
Medicine Products: